Isomorphic Labs总裁Colin Murdoch在巴黎接受Fortune采访时透露：「有人正坐在我们伦敦国王十字区的办公室里，与AI合作设计抗癌药物。 这正在发生。 」 ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

2025年，Google旗下的Isomorphic Labs宣布将启动首个人类临床试验，标志着AI药物设计技术的重大进展。该公司由DeepMind分拆而成，致力于通过AI技术攻克人类面临的各种疾病。Isomorphic Labs总裁Colin ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

【观网财经丨智能早报 7月8日】谷歌AI制药将进行首次人体试验 Isomorphic Labs总裁兼谷歌DeepMind首席商务官Colin Murdoch透露，Isomorphic ...

• Alphabet旗下Isomorphic Labs的总裁科林·默多克（Colin Murdoch）向《财富》杂志透露，该实验室正准备启动人工智能设计药物的人体试验。这家源自DeepMind ...

Google DeepMind's spinoff Isomorphic Labs is set to begin human trials of a drug desinged completely by Artificial ...

自第一批人工智能药物发现公司出现以来的十年左右，大部分行动都处于早期发现阶段，机器尚未能够取代实验室测试。近几年跨国药企纷纷借助股权投资、管线授权、联合研发等多种模式，加速与AI制药企业的深度融合。万联证券指出，药企愿意支付高额预付款，表明AI生成分子的可信度提升，企业合作共担风险有利于推动AI制药从“概念”走向“现金流”。